Wang et al. found that LAG-3 and its novel ligand fibrin 1 (FGL1)/LAG-3 functions as new immune checkpoint pathway independent of the PD-1/PD-L1 pathway, and may be new target of cancer resistant to anti-PD1 treatment [12]. Here, LAG3 is linked to cancer.